Skip to content

Adult & Pediatric ECMO: Epidemiology, Clinical characteristics and Outcomes: An Asian Multicenter Study (APECAS)

Adult & Pediatric ECMO: Epidemiology, Clinical characteristics and Outcomes: An Asian Multicenter Study (APECAS)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20241018002
Enrollment
500
Registered
2024-10-18
Start date
2025-10-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe cardio-pulmonary failure required ECMO therapy ARDS, cardiogenic shock, refractory, ECMO, outcome

Interventions

Infants, children or adult who required extracorporeal life suport
Treatment
ECMO Utilization in both Adult and Pediatrics

Sponsors

THE ROYAL COLLEGE OF PEDIATRICIANS OF THAILAND & PEDIATRIC SOCIETY OF THAILAND
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Days to 80 Years

Inclusion criteria

Inclusion criteria: 1 Infants, Children and Adults aged between Newborn through 18 year old (Ped) and Adult age more than 18 years to 80 years with diagnosis of Acute severe cardio-pulmonary or cardiovascular failure and required extracorporeal life support 2 No Exclusion Criteria eg Multiple organ failure

Exclusion criteria

Exclusion criteria: End- stage disease e.g. advanced metastasis tumors - Severe congenital anomaly - Age > 80 years old - Terminal Illness or Limited Life Expectancy: Exclude participants with terminal illnesses or a limited life expectancy, as ECMO is typically considered a treatment option for reversible conditions. - Uncontrolled Bleeding or Coagulation Disorders: Exclude individuals with severe bleeding disorders or coagulopathy that cannot be adequately managed during ECMO support. - Severe Neurological Injury: Exclude participants with severe neurological injury or irreversible brain damage, as ECMO may not be beneficial in these cases. - Inability to Provide Informed Consent: Exclude participants who are unable to provide informed consent themselves or lack a legally authorized representative to provide consent on their behalf.

Design outcomes

Primary

MeasureTime frame
survival at hospital discharged Rate of survival,Morbidity any time point during ecmo treatment bleeding,ICU Ventilator day 28 days of ICU admission days on Ventilator in ICU

Secondary

MeasureTime frame
quality of life End of hospital discharged Clinical Score

Countries

Thailand

Contacts

Public ContactRujipat Samransamruajkit

King Chulalongkorn Memorial Hospital

rujipatrs@gmail.com6622564651

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026